CRISPR Therapeutics AG (CRSP) Income from Continuing Operations (2015 - 2026)

CRISPR Therapeutics AG has disclosed Income from Continuing Operations across 12 years of filings, most recently posting -$91.2 million for Q2 2026.

• In Q2 2026, Income from Continuing Operations rose 56.27% year-over-year to -$91.2 million; the TTM figure through Jun 2026 stood at -$483.7 million (up 5.07% YoY), while the FY2025 annual figure was -$614.1 million, down 50.53% from the prior year.
• Income from Continuing Operations came in at -$91.2 million for Q2 2026 at CRISPR Therapeutics AG, up from -$122.9 million in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of $58.6 million in Q4 2023 to a low of -$208.6 million in Q2 2025.
• Average Income from Continuing Operations over 5 years is -$115.2 million, with a median of -$114.7 million recorded in 2022.
• Year-over-year, Income from Continuing Operations soared 151.93% in 2023 and tumbled 234.81% in 2024.
• Over 5 years, Income from Continuing Operations stood at -$112.9 million in 2022, then soared by 151.93% to $58.6 million in 2023, then plunged by 234.81% to -$79.0 million in 2024, then tumbled by 106.47% to -$163.1 million in 2025, then jumped by 44.1% to -$91.2 million in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were -$91.2 million in Q2 2026, -$122.9 million in Q1 2026, and -$163.1 million in Q4 2025.